You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Carbidopa, an iron chelator and an ABCG2 inducer, for treatment of gouty arthritis

    SBC: South Plains Biotechnology, Inc            Topic: NIAMS

    Our goal is to evaluate the efficacy of the FDA approved drug Carbidopa for the treatment of gouty arthritis in mouse modelsCarbidopa is used to treat Parkinson s diseasebut always in combination of L DOPAnever alone by itselfGouty arthritis is caused by deposition of monosodium urateMSUcrystals in jointsinitiating inflammation and arthritisInterestinglygout is not always directly related to incre ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Oral Enzymatic Management of Phenylketonuria

    SBC: ABRI SCIENCE, LLC            Topic: 300

    PhenylketonuriaPKUis a genetic disorder of metabolism characterized by a pathological elevation of phenylalaninePhein the body stemming from a dysfunctional phenylalanine hydroxylase enzymePAHThe resulting high concentrations of Phexcan result in severe intellectual disabilitybehavioral problemsand neurological deficitse gseizuresStrict control of dietary Phe is the primary treatment for PKU curre ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Granulocyte/Monocyte Precursors to Treat Neutropenia after Cancer Chemotherapy

    SBC: CORD BLOOD PLUS, INC.            Topic: 102

    PROJECT SUMMARY ABSTRACT The objective of this proposal is to move our product forward toward commercialization by improving the quality of life for breast cancer chemotherapy patientsThis will be achieved by the following Specific AimsAimwill optimize differentiation of GMPs and neutrophil lineages in culture in response to G CSFThis will be assessed by flow cytometry to quantify production of ne ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. The first commercial rapid diagnostic test to detect Paragonimus infections

    SBC: NANOCOMPOSIX, INC.            Topic: NIAID

    Abstract We propose an ultrasensitive rapid diagnostic testRDTto detect exposure to pulmonary flukes of the genus ParagonimusParagonimiasis affects an estimatedmi l l ion people and remains amongst the most neglected of all neglected tropical diseasesNTDsThis trematode is acquired upon ingestion of raw or undercooked freshwater crustaceans and migrates to the lungs where it forms cystsTreatment is ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Targeting lipid rafts for treatment of asthma

    SBC: RAFT PHARMACEUTICALS LLC            Topic: NIAID

    PROJECT SUMMARY Asthma, characterized by airways obstruction with symptoms of wheezing, shortness of breath, chest tightness and consequently cough, remains a significant health problem. While advances in bronchodilator, corticosteroid and Th2-targeting therapy allow for well-controlled asthma in a large population of patients, subjects with severe, corticosteroid resistant asthma require frequent ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Gallium 68 Tilmanocept for PET Imaging of Atherosclerosis Plaques

    SBC: Navidea Biopharmaceuticals, Inc.            Topic: NHLBI

    Myocardial infarctionsMIor heart attacksischemic strokesISand peripheral artery diseasePADtogether considered cardiovascular diseaseCVDare all commonly caused by the same underlying pathologyatherosclerosisMIs and ISs are the leading causes of death and disability worldwideAtherosclerosis is a progressive pathology that develops asymptomatically over the course of many years as inflammatory plaque ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Targeting neurotoxic alpha-synuclein aggregates for Parkinson's disease therapy.

    SBC: Vova Ida, LLC            Topic: 999

    SUMMARYParkinsonandapos s diseasePDis the second most prevalent neurodegenerative disorder after Alzheimerandapos s diseaseADaffecting more thanmillion people in the United StatesBecause age is the major risk factorthe prevalence of both diseases is steadily increasing as our population agesPD belongs to the group of protein misfolding neurodegenerative diseases that are due to the misfolding and ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Bone Metastasis Specific 18F PET Imaging Probe for Breast Cancer

    SBC: BIOVINC, LLC            Topic: 102

    ABSTRACTBreast CancerBCis the leading cause of cancer death for woman in the USBreast cancer is treated by a combination of surgeryradiationand various types of chemo and targeted therapeutic strategiesApproximately half of patients who have positive sentinel lymph nodes at surgeryand as many asof patients who do noteventually present with metastatic diseaseOverof BC patients eventually have skele ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    Project Summary Bacillus anthracis (Ba) is a Gram-positive spore forming bacterium that is listed as an agent of highest concern (Category A) by NIAID and CDC. Ba is easy to grow, and its spores can be formulated into highly stable powder form and disseminated as aerosol or used to contaminate food or water. In 2001, letters laced with powdered anthrax spores were mailed to several US politicians. ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Targeting lipid rafts for treatment of migraine

    SBC: RAFT PHARMACEUTICALS LLC            Topic: NINDS

    PROJECT SUMMARY Migraine is a highly prevalent condition with an extraordinarily negative impact on quality of life and represents a heavy socioeconomic burden to the societyprimarily because of decreased working efficiency and workdays lostManagement of migraine has become increasingly pharmacological during recent yearsWhile several therapeutic options existmost of the prophylactic drugs current ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government